Parallel Advisors LLC cut its holdings in Celgene Co. (NASDAQ:CELG) by 11.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,155 shares of the biopharmaceutical company’s stock after selling 956 shares during the period. Parallel Advisors LLC’s holdings in Celgene were worth $710,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Celgene by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 54,115,735 shares of the biopharmaceutical company’s stock worth $5,002,460,000 after acquiring an additional 929,823 shares during the last quarter. Northern Trust Corp boosted its holdings in Celgene by 0.8% during the 2nd quarter. Northern Trust Corp now owns 9,093,790 shares of the biopharmaceutical company’s stock valued at $840,630,000 after acquiring an additional 69,542 shares during the period. Renaissance Technologies LLC boosted its holdings in Celgene by 85.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock valued at $826,024,000 after acquiring an additional 4,122,685 shares during the period. Nuveen Asset Management LLC boosted its holdings in Celgene by 707.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock valued at $413,836,000 after acquiring an additional 3,922,247 shares during the period. Finally, TIG Advisors LLC boosted its holdings in Celgene by 77.3% during the 2nd quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock valued at $331,270,000 after acquiring an additional 1,562,004 shares during the period. 72.31% of the stock is currently owned by institutional investors.

Shares of CELG stock traded up $0.21 during mid-day trading on Friday, hitting $109.21. The stock had a trading volume of 130,811 shares, compared to its average volume of 3,870,767. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $109.07. The firm has a market capitalization of $76.64 billion, a P/E ratio of 14.35, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41. The firm’s 50-day moving average is $102.33 and its two-hundred day moving average is $96.68. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.89 and a quick ratio of 2.80.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business had revenue of $4.52 billion during the quarter, compared to analysts’ expectations of $4.39 billion. During the same period in the prior year, the business earned $2.29 EPS. The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. Analysts expect that Celgene Co. will post 10.7 EPS for the current year.

CELG has been the subject of a number of recent analyst reports. Standpoint Research cut Celgene from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Co set a $110.00 price objective on Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Cowen restated a “hold” rating and set a $102.00 price objective on shares of Celgene in a report on Tuesday, July 30th. Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective for the company. in a report on Friday, November 1st. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Celgene presently has an average rating of “Hold” and a consensus target price of $97.31.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.39% of the stock is currently owned by corporate insiders.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is a blue-chip stock?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.